Compare · RVMD vs WENA
RVMD vs WENA
Side-by-side comparison of Revolution Medicines Inc. (RVMD) and ANEW MEDICAL INC. (WENA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RVMD and WENA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD carries a market cap of $34.65B.
- RVMD has hit the wire 13 times in the past 4 weeks while WENA has been quiet.
- RVMD has more recent analyst coverage (25 ratings vs 0 for WENA).
- Company
- Revolution Medicines Inc.
- ANEW MEDICAL INC.
- Price
- $162.84+3.15%
- $0.75-2.99%
- Market cap
- $34.65B
- -
- 1M return
- +10.42%
- -
- 1Y return
- +310.49%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2022
- News (4w)
- 13
- 0
- Recent ratings
- 25
- 0
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest RVMD
- Officer Mancini Anthony sold $720,490 worth of shares (4,615 units at $156.12), decreasing direct ownership by 8% to 49,975 units (SEC Form 4) to satisfy withholding tax
- Officer Goldsmith Mark A sold $1,564,310 worth of shares (10,020 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 267,330 units (SEC Form 4) to satisfy withholding tax
- General Counsel Cislini Jeff sold $336,749 worth of shares (2,157 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 56,521 units (SEC Form 4) (for tax liability)
- Chief Financial Officer Anders Jack sold $424,956 worth of shares (2,722 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,269 units (SEC Form 4) to satisfy withholding tax
- Officer Kelsey Stephen Michael sold $651,798 worth of shares (4,175 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 291,876 units (SEC Form 4) (withholding tax)
- Chief Operating Officer Horn Margaret A exercised 90,000 shares at a strike of $30.82 and sold $14,972,110 worth of shares (93,575 units at $160.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 154,647 units (SEC Form 4) to cover taxes
- SEC Form 144 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.
Latest WENA
- SEC Form EFFECT filed by ANEW MEDICAL INC.
- ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.
- SEC Form S-1 filed by ANEW MEDICAL INC.
- Healthy Longevity is One of Key Development Goals of ANEW's Novel Gene Therapy
- ANEW MEDICAL INC. filed SEC Form 8-K: Leadership Update
- ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility
- ANEW MEDICAL INC. filed SEC Form 8-K: Leadership Update
- ANEW MEDICAL INC. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- ANEW MEDICAL, INC. Acquires License to Needle-Free Dry Powder Autoinjector from Transfertech Sherbrooke ("TTS")
- SEC Form 10-Q filed by ANEW MEDICAL INC.